Evidence map›Paper›PMID 37605256›Full record

ArticleJournal of nanobiotechnology2023

Dendrimer-conjugated isotretinoin for controlled transdermal drug delivery.

Tianqi Zhao, Mingwei Zhou, Ronghui Wu, Huaxin Wang, Christos C Zouboulis, Mingji Zhu, Myongsoo Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tianqi Zhao *Department of Dermatology, China-Japan Union Hospital of Jilin University, Changchun, 130031, Jilin, China.
Mingwei Zhou *Department of Dermatology, China-Japan Union Hospital of Jilin University, Changchun, 130031, Jilin, China.
Ronghui WuDepartment of Dermatology, China-Japan Union Hospital of Jilin University, Changchun, 130031, Jilin, China.
Huaxin WangDepartment of Chemistry, Fudan University, Shanghai, 200438, China.
Christos C ZouboulisDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
Mingji ZhuDepartment of Dermatology, China-Japan Union Hospital of Jilin University, Changchun, 130031, Jilin, China. zmj@jlu.edu.cn.
Myongsoo LeeDepartment of Chemistry, Fudan University, Shanghai, 200438, China. mslee@fudan.edu.cn.

Funding

the Department of Science and Technology of the Jilin Province 20220204004YY
6 · The paper itself

Abstract

backgroundIn the present study, we aimed to develop a novel isotretinoin delivery model for treating skin diseases, revealing its potential advantages in drug delivery and targeted therapy. Using a self-assembly strategy, we grafted a dendrimer, based on a well-defined branched structure for nanomedical devices, with a well-defined nanoarchitecture, yielding spherical, highly homogeneous molecules with multiple surface functionalities. Accordingly, a self-assembled dendrimer-conjugated system was developed to achieve the transdermal delivery of isotretinoin (13cRA-D).

resultsHerein, 13cRA-D showed remarkable controlled release, characterized by slow release in normal tissues but accelerated release in tissues with low pH, such as sites of inflammation. These release characteristics could abrogate the nonteratogenic side effects of isotretinoin and allow efficient skin permeation. Moreover, 13cRA-D exhibited high therapeutic efficacy in acne models. Based on in vitro and in vivo experimental results, 13cRA-D afforded better skin penetration than isotretinoin and allowed lesion targeting. Additionally, 13cRA-D induced minimal skin irritation.

conclusionOur findings suggest that 13cRA-D is a safe and effective isotretinoin formulation for treating patients with skin disorders.

Indexed as

Acne VulgarisDendrimersDrug Delivery SystemsHumansInflammationIsotretinoinSkinDendrimersIsotretinoinAcneDendrimerIsotretinoinNanoconjugatePsoriasisTransdermal drug delivery

Identifiers

PMID37605256
PMCPMC10464058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.